N,N′,N′-triacetylglucosamine, an inhibitor of lysozyme, prevents myocardial depression in Escherichia coli sepsis in dogs*
Authors:
- Steven N. MinkSMSteven N. Mink
- Hans JacobsHJHans Jacobs
- Krika DukeKDKrika Duke
- Deepak BoseDBDeepak Bose
- Zhao-Qin ChengZCZhao-Qin Cheng
- R. Bruce LightRLR. Bruce Light
- 1 January 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 32 (1) , 184-193
Abstract
Reversible myocardial depression in sepsis has been ascribed to the release of inflammatory mediators. We recently found that lysozyme c (Lzm-S), consistent with that originating from the spleen, was a mediator of myocardial depression in an Escherichia coli model of septic shock in dogs. We further showed in a right ventricular trabecular (RVT) preparation that Lzm-S’s depressant activity could be blocked by N,N′,N’ triacetylglucosamine (TAC), a competitive inhibitor of Lzm-S. We hypothesized that Lzm-S binds to or cleaves a cardiac membrane glycoprotein, thereby interfering with myocardial contraction in sepsis. In the present study, we examined whether TAC could prevent myocardial depression in an in vivo preparation and whether other related N-acetylglucosamine (NAG) structures could also inhibit Lzm-S’s effect in RVT. Randomized experimental study. University laboratory. Anesthetized, mechanically ventilated dogs. We produced sepsis by infusion of E. coli over an approximately 6-hr period. We examined the effect of TAC on stroke work, our primary index of myocardial function, when treatment was administered before sepsis (pretreatment) and after 1.5 hrs (early treatment study) and 3.5 hrs of sepsis (late treatment study; LTS). In the pretreatment study and early treatment study, myocardial depression would have not yet occurred but would have already been present in the late treatment study. In RVT, we assessed the effect of other NAG oligosaccharides and variants to the NAG structure on Lzm-S’s depressant activity. In pretreatment and the early treatment study, TAC prevented the reduction in stroke work observed in nontreated septic groups but did not reverse the reduction found in the late treatment study. In RVT, of the compounds tested, only N,N′-diacetylglucosamine showed an inhibitory effect. We found that TAC, a competitive inhibitor of Lzm-S, prevented myocardial depression in experimental sepsis. Only specific NAG structures are inhibitory to Lzm-S’s depressant activity. TAC may be useful in attenuating cardiovascular collapse in sepsis.Keywords
This publication has 25 references indexed in Scilit:
- Lysozyme: a mediator of myocardial depression and adrenergic dysfunction in septic shock in dogsJournal of Molecular and Cellular Cardiology, 2003
- A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance.Journal of Clinical Investigation, 1985
- Profound but Reversible Myocardial Depression in Patients with Septic ShockAnnals of Internal Medicine, 1984
- Lysozyme Activity in Human Neutrophilic GranulocytesBritish Journal of Haematology, 1973
- Influence of a Myocardial Depressant Factor on Physiologic Properties of Cardiac MuscleExperimental Biology and Medicine, 1970
- Use of synthetic substrates to study binding and catalysis by lysozymeBiochemistry, 1969
- Mechanism of Lysozyme ActionScience, 1969
- Characterization of a myocardial depressant factor present in hemorrhagic shockAmerican Journal of Physiology-Legacy Content, 1967
- LYSOZYME IN BONE MARROW AND PERIPHERAL BLOOD CELLSJournal of Histochemistry & Cytochemistry, 1966
- On a remarkable bacteriolytic element found in tissues and secretionsProceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character, 1922